11:45 AM EDT, 07/31/2024 (MT Newswires) -- Rhythm Pharmaceuticals ( RYTM ) said Wednesday that it received expanded marketing authorization for Imcivree from the European Commission to include children between 2 and 6 years old with rare neuroendocrine diseases.

The expanded authorization for Imcivree, or setmelanotide, now includes children 2 years up to under 6 years old with obesity due to Bardet Biedl syndrome or pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency, the biopharmaceutical company said.

Rhythm Pharmaceuticals ( RYTM ) said Imcivree is the first ever precision medicine approved in the European Union for the control of hunger and treatment of obesity in adults and children.

Price: 47.80, Change: +0.14, Percent Change: +0.29